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Abstract
Background: The p38a mitogen-activated protein kinase (MAPK) is a critical mediator of myoblast differentiation,
and does so in part through the phosphorylation and regulation of several transcription factors and chromatin
remodelling proteins. However, whether p38a is involved in processes other than gene regulation during
myogenesis is currently unknown, and why other p38 isoforms cannot compensate for its loss is unclear.
Methods: To further characterise the involvement of p38a during myoblast differentiation, we developed and
applied a simple technique for identifying relevant in vivo kinase substrates and their phosphorylation sites. In
addition to identifying substrates for one kinase, the technique can be used in vitro to compare multiple kinases in
the same experiment, and we made use of this to study the substrate specificities of the p38a and b isoforms.
Results: Applying the technique to p38a resulted in the identification of seven in vivo phosphorylation sites on six
proteins, four of which are cytoplasmic, in lysate derived from differentiating myoblasts. An in vitro comparison
with p38b revealed that substrate specificity does not discriminate these two isoforms, but rather that their
distinguishing characteristic appears to be cellular localisation.
Conclusion: Our results suggest p38a has a novel cytoplasmic role during myogenesis and that its unique cellular
localisation may be why p38b and other isoforms cannot compensate for its absence. The substrate-finding
approach presented here also provides a necessary tool for studying the hundreds of protein kinases that exist and
for uncovering the deeper mechanisms of phosphorylation-dependent cell signalling.
Keywords: differentiation, FSBA, kinase assay, mitogen-activated protein kinase, myoblast, p38, phosphorylation,
quantitative MS
Background
Protein kinases are well-known regulators of cell signal-
ling and cellular behaviour that execute their function
through the covalent attachment of an ATP-derived
phosphate to protein substrates. To understand the
function of any protein kinase on a large and cell-wide
scale first requires the development of a substrate
screening technique that allows for the proteins phos-
phorylated by a kinase of interest to be comprehensively
identified, ideally in a single experiment. Although
substrate-finding techniques exist, they are hindered by
problems that prevent them from being easily or readily
employed [1-4] and are generally limited to providing in
vitro substrate identifications that may or may not be
relevant in vivo. In vivo approaches currently available,
such as that employed by Holt et al. [5], can associate a
kinase with in vivo phosphorylation events, but direct
phosphorylation cannot be inferred without additional
experimentation. A simple technique that can identify
direct in vivo substrates is an obvious need for the field.
The mitogen-activated protein kinase p38a is involved
in several cellular processes, but its critical role during
differentiation, and particularly the differentiation of
myoblasts, has been a major focus. At the initiation of
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late several transcription factors and chromatin remo-
delling proteins, thereby inducing the expression of a
myogenic gene program [6]. Although much is known
about p38a’s role in this process, it is likely very partial,
and whether p38a plays an important role in other pro-
cesses during myoblast differentiation, such as cell
fusion or sarcomere formation, is unknown. At the
same time, there are questions regarding the other p38
isoforms and their role, or lack thereof, in myogenesis.
p38b is also expressed in myoblasts and is activated in
the same manner as p38a, but despite having a kinase
domain 75% identical to that of p38a (72% sequence
identity overall), p38b is unable to compensate for the
loss of p38a, even when overexpressed [7-9]. The
obvious and suspected explanation is that there are criti-
cal myogenic phosphorylations specific to the a isoform,
but these have yet to be discovered and whether this
assumption is correct is unknown.
Here we describe a simple approach for substrate find-
ing that can be used to identify in vitro and in vivo sub-
strates. The technique begins with treatment of cell
lysate to inactivate endogenous kinases, followed by an
in vitro assay using an exogenous kinase of interest, and
concludes with quantitative mass spectrometry (MS) to
identify phosphorylation sites specific to the added
kinase. By using lysate derived from vehicle- or inhibi-
tor-treated cells, this in vitro approach can be simulta-
neously coupled with biologically relevant information
to identify direct substrates regulated by the kinase of
interest in vivo. Applying this technique to p38a with
lysate from differentiating myoblasts resulted in the
identification of several new in vivo substrates that sug-
gest novel functions for p38a during myogenesis. We
did not identify a single phosphorylation specific to the
p38a isoform compared with p38b,a tl e a s ti nt e r m so f
in vitro substrate specificity, but we did see a clear dif-
ference in cellular localisation during myoblast differen-
tiation. This leads us to propose that although the
kinase domains of p38a and b likely have the same
capacity to phosphorylate substrates, there are major
differences in actual substrate specificity in an in vivo
context.
Methods
Cell culture
C2C12 cells were grown in Dulbecco’s modified Eagle’s
medium (DMEM) supplemented with 10% (vol/vol) foe-
tal bovine serum with 100 U/ml penicillin, 100 μg/ml
streptomycin and 250 ng/ml amphotericin B. To induce
differentiation, cells were grown to 85-90% confluence,
and the medium was changed to DMEM with 2% horse
serum supplemented with penicillin, streptomycin and
amphotericin B as described above. FLAG-tagged p38a
and p38b were acquired from Addgene (Cambridge,
MA, USA) [10]. Constructs were transfected into C2C12
myoblasts with Lipofectamine 2000 reagent (Invitrogen,
Carlsbad, CA, USA) according to the manufacturer’s
instructions. To inhibit p38 activity, SB 202190 (Pro-
mega, Madison, WI, USA) solubilised in dimethyl sulph-
oxide (DMSO) or DMSO as control was added to
differentiation media at 48 hours following the induction
of differentiation, and medium with inhibitor was chan-
ged daily.
Immunofluorescence
Cells were fixed with 4% formaldehyde and stained with
the following antibodies: Flag M2 (1:1,000 dilution;
Sigma-Aldrich, St Louis, MO, USA), myosin heavy chain
(MyHC) (1:20 dilution; Developmental Studies Hybri-
doma Bank, Department of Biology, University of Iowa,
Iowa City, IA, USA), Alexa Fluor 488 goat anti-mouse
antibody (1:1,000 dilution; Molecular Probes/Invitrogen)
and Alexa Fluor 555 goat anti-mouse antibody (1:1,000
dilution; Molecular Probes/Invitrogen). The differentia-
tion index was calculated as the number of MyHC-posi-
tive nuclei divided by the total number of nuclei. The
fusion index was quantified as the number of nuclei per
MyHC-positive cell. Five fields of view at ×20 magnifica-
tion were counted and averaged per replicate, with a
total of three replicate experiments.
Statistical analysis
Statistical analyses were performed using StatPlus soft-
ware (AnalystSoft Inc; http://www.analystsoft.com/en/
products/statplus/). The data shown are means with SD,
and Student’s t-tests were performed to determine sig-
nificance for the differentiation and fusion indices.
Western blot analysis
For Western blot analysis, cells were lysed in radioim-
munoprecipitation assay (RIPA) buffer (50 mM
Tris∙HCl, pH 7.5, 1% Nonidet P-40, 0.1% SDS, 150 mM
NaCl, 1 mM ethylenediaminetetraacetic acid (EDTA), 50
mM NaF, 200 μMN a 3VO4, 1 mM phenylmethanesul-
phonylfluoride (PMSF), 10 μg/ml aprotinin, 10 μg/ml
leupeptin and 10 μg/ml pepstatin), and 5× Laemmli buf-
fer (300 mM Tris, pH 6.8, 0.01% bromophenol blue,
10% SDS, 50% glycerol and 5% b-mercaptoethanol) was
added to 25 μg of protein per sample to a final concen-
tration of 1× for SDS-PAGE. For fractionation, cells
were lysed in hypotonic buffer (10 mM 4-(2-hydro-
xyethyl)-1-piperazineethanesulphonic acid (HEPES), pH
7.5, 1.5 mM MgCl2,1 0m MK C l ,0 . 5m Md i t h i o t h r e i t o l
( D T T ) ,5 0m MN a F ,2 0 0μMN a 3VO4,1m MP M S F ,1 0
μg/ml aprotinin, 10 μg/ml leupeptin and 10 μg/ml pep-
statin) and left on ice for 10 minutes. Cells were then
p a s s e dt h r o u g ha2 5 - g a u g en e e d l et h r e et i m e sa n d
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The supernatant was collected as whole cytoplasm. For
further fractionation of the cytoplasm, the supernatant
was centrifuged again at 5,000 g to pellet mitochondria
and membrane fractions. The supernatant was then col-
lected and centrifuged at 100,000 g to pellet any remain-
ing cell particles, and the resulting supernatant was
collected as cytosol. RIPA buffer was added to all frac-
tions to a final concentration of 1× for complete lysis.
Recombinant phosphorylated p38a (Millipore, Billerica,
MA, USA) was dephosphorylated using l-protein phos-
phatase (New England Biolabs, Inc, Ipswich, MA, USA)
by adding 800 U of phosphatase to 200 ng of p38a
diluted in l-phosphatase buffer, and the sample was
assayed at 30°C for 1 hour. Antibodies used for blotting
were as follows: a-actinin (1:125 dilution; Abcam, Cam-
bridge, MA, USA), COX IV (1:1,000 dilution; Abcam),
GRP78 (1:500 dilution; Cell Signaling Technology, Dan-
v e r s ,M A ,U S A ) ,l a m i nA / C( 1 : 5 0 0d i l u t i o n ;A b c a m ) ,
MyHC (1:100 dilution; Developmental Studies Hybri-
doma Bank), MyoD (1:1,000 dilution; Santa Cruz Bio-
technology, Santa Cruz, CA, USA), myogenin (1:100
dilution; Developmental Studies Hybridoma Bank),
neural cell adhesion molecule (1:200 dilution; Abcam),
p38a (1:500 dilution; Cell Signaling Technology), phos-
pho-p38 (1:500 dilution; Abcam) and b-tubulin (1:1,000
dilution; Developmental Studies Hybridoma Bank). An
Alpha Innotech HD2 imaging system (R&D Systems,
Minneapolis, MN, USA) was used to quantify phospho-
p38 and tubulin expression.
FSBA treatment and substrate labelling
Cells were lysed in Nonidet P-40 buffer (50 mM
Tris∙HCl, pH 7.8, 150 mM NaCl, 1% (vol/vol) Nonidet
P-40, 1 mM PMSF, 10 μg/ml aprotinin, 10 μg/ml leu-
peptin and 10 μg/ml pepstatin). Lysate was treated at a
concentration of 2 mg/ml with 20 mM 5’-4-fluorosul-
phonylbenzoyladenosine (FSBA) solubilised in DMSO
and placed at 30°C for 1 hour. The sample was then
diluted down to 1:5 with Nonidet P-40 buffer minus
protease inhibitors and desalted using Millipore Amicon
ultrafiltration columns with a 10 kDa molecular weight
cutoff. Following concentration, the sample was diluted
to 4 mg/ml with Nonidet P-40 buffer and diluted 1:2
with 2× kinase assay buffer (40 mM 3-morpholinopro-
pane-1-sulphonic acid (MOPS), pH 7.2, 50 mM b-gly-
cerophosphate, 10 mM ethylene glycol tetraacetic acid
(EGTA), 2 mM Na3VO4, 2 mM DTT, 50 mM MgCl2,
400 μMc o l dA T Pa n d5μCi [g-
32P]ATP). Recombinant
p38a or p38b (Millipore) was added to a final concen-
tration of 0.5% (wt/wt) total protein. Control and
kinase-added samples were assayed at 30°C for 1.5
hours. For one-dimensional SDS-PAGE, 5× Laemmli
buffer was added following the assay to 1×, and the
sample was electrophoresed. For two-dimensional elec-
trophoresis, 17-cm ReadyStrip immobilised pH gradient
(IPG) strips (Bio-Rad Laboratories, Hercules, CA, USA)
were directly rehydrated with labelled lysate diluted in
rehydration buffer (7 M urea, 2 M thiourea, 4% 3-[(3-
cholamidopropyl)dimethylammonio]-1-propanesulpho-
nate (CHAPS) and 1% DTT) following the manufac-
turer’s directions. Isoelectric focusing was performed on
a PROTEAN IEF Cell (Bio-Rad Laboratories) under the
following conditions: 200 V for 1 hour, 500 V for 1
hour, 5,000 V ramp for 5 hours and 5,000 V for 80,000
VH. IPG strips were then equilibrated following the
manufacturer’si n s t r u c t i o n sa n do v e r l a i do n t oa1 2 %
SDS-PAGE gel. Following electrophoresis, gels were
dried and imaged. For one-dimensional electrophoresis,
100 μg of lysate was used per reaction. For two-dimen-
sional electrophoresis, 300 μg of lysate was used.
For in vitro substrate identification, assays were per-
formed as described above with the following modifica-
tions. A quantity of 1.5 mg of lysate was treated with
FSBA, the sample was desalted and 2× kinase assay buf-
fer was added (40 mM MOPS, pH 7.2, 50 mM b-glycer-
o p h o s p h a t e ,1 0m ME G T A ,2m MN a 3VO4,2m M
DTT, 50 mM MgCl2 and 2 mM cold ATP). The sample
was then split into three 500-μga l i q u o t s ,a n d5μgo f
heat-inactivated p38a was added to the control, 5 μgo f
active p38a was added to the second aliquot and 5 μg
of active p38b was added to the third aliquot. The sam-
ples were then assayed for 3 hours at 30°C.
For in vivo substrate identification, assays were per-
formed as above with the following modifications. At 48
hours of differentiation, cells were treated with 5 μMo f
SB 202190 or an equivalent amount of DMSO as vehi-
cle. Twenty-four hours later the cells were lysed in Non-
idet P-40 buffer. Lysate (1 mg) from DMSO-treated cells
or 2× 1 mg of lysate from SB 202190-treated cells was
inhibited with FSBA, the samples were desalted and 2×
kinase assay buffer was added to each. A quantity of 5
μgo fa c t i v ep 3 8 a was added to one of the lysate ali-
quots from SB-treated cells. The samples were then
assayed for 3 hours at 30°C.
Dimethyl labelling
After assaying the samples, they were precipitated by
methanol chloroform, then redissolved in 200 μlo f8M
urea and 50 mM Tris∙HCl, pH 8.1, with sonication. The
samples were then reduced with 20 mM DTT for 1
hour at 60°C and alkylated by 100 mM iodoacetamide
for 30 minutes at room temperature in the dark. Subse-
quently, the samples were diluted to 2 M urea with 50
mM Tris∙HCl, pH 8.1, and digested with trypsin at a
protein-to-trypsin ratio of 50:1 (wt/wt) for 16 hours at
37°C. Next, the digested samples were acidified to pH 2
using 10% (vol/vol) formic acid. Dimethyl labelling of
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and is described briefly as follows. The acidified peptides
were loaded onto C18 solid phase extraction (SPE) col-
umns (50 mg of packing material). After brief washing
with 50 mM sodium phosphate buffer, pH 7.5, 3 ml of
light, intermediate and heavy labelling reagents were
loaded onto C18 SPE columns trapped with control,
p38a-a n dp 3 8 b-labelled samples, respectively. After
being washed with 0.1% (vol/vol) formic acid, the
labelled samples were eluted with 80% acetonitrile
(ACN) (vol/vol) and 0.1% (vol/vol) formic acid, then
dried by vacuum centrifugation.
Phosphopeptide enrichment
Phosphopeptide enrichment by TiO2 was carried out as
reported previously [12] with modifications. The dried
samples were redissolved with 65% ACN/2% trifluoroa-
cetic acid (TFA)/saturated glutamic acid and combined.
TiO2 beads suspended in 65% ACN/2% TFA/saturated
glutamic acid were added into the above samples with a
peptide to TiO2 bead ratio of 1:4 (wt/wt). After being
nutated for 40 minutes, the TiO2 beads were recovered
by centrifugation and washed thoroughly with 65%
ACN/2% TFA. Finally, the enriched phosphopeptides
were eluted with 10% (vol/vol) NH3·H2Oa n dd r i e db y
vacuum centrifugation.
Online liquid chromatography tandem mass spectrometry
analysis
Online liquid chromatography tandem mass spectrome-
try (LC-MS/MS) analysis was performed as reported
previously [13,14] with modifications. The dried sample
was redissolved with 0.1% formic acid and loaded onto a
biphasic trap column (200 μmI D×1 0c m ;5 - c m
reversed phase column packed with ReproSil-Pur C18
resin (5 μm at 200 Å; Dr.Maisch GmbH, Ammerbuch-
Entringen, Germany) and a 5-cm monolith strong cation
exchange (SCX) column). The trapped phosphopeptides
were eluted from the trap column onto a C18 tip col-
umn (75 μmI D×2 0c m ,3μma t2 0 0Å ;D r . M a i s c h
GmbH) by a series of salt washes at increasing concen-
trations (0, 5, 10, 15, 20, 25, 30, 35, 40, 45, 50, 55, 60,
70, 80, 90, 100, 150, 200 and 1,000 mM). Each fraction
was then separated by reversed phase-based gradient
elution and detected using an LTQ Orbitrap XL Fourier
transform mass spectrometer (Thermo Scientific, Wal-
tham, MA, USA). The reversed phase gradient was set
as follows: 0% to 5% ACN for 2 minutes, 5% to 30%
ACN for 90 minutes and 30% to 80% ACN for 5 min-
utes. After flushing with 80% ACN for 10 minutes, the
column was equilibrated with 0.1% formic acid aqueous
solution for 13 minutes. The LTQ Orbitrap XL Fourier
transform mass spectrometer was operated in positive
ionization mode. A voltage of 1.8 kV was applied. MS
and MS/MS spectra were acquired in a data-dependent
mode, and one full MS scan was followed by ten MS/
MS scans. The resolution was set at 60,000 at m/z 400
after accumulation to a target value of 500,000.
Protein identification and quantification
All MS/MS spectra in one acquired raw file were con-
verted to a single *.mgf file using DTASuperCharge ver-
sion 2.0a7 (Matrix Science, Boston, MA, USA). The *.
mgf file was queried against the International Protein
Index mouse database version 3.52 (EMBL-EBI; http://
www.ebi.ac.uk/IPI/IPIhelp.html) using Mascot version
2.1 (Matrix Science). To evaluate the false discovery rate
(FDR), reversed sequences were appended to the data-
base. Cysteine residues were searched as a static modifi-
cation of +57.0215 Da; methionine residues were
searched with a variable modification of +15.9949 Da;
and serine, threonine and tyrosine residues were
searched with a variable modification of +79.9663 Da.
Light, intermediate and heavy dimethylation of peptide
amino termini and lysine residues were set as variable
modifications of +28.0313 Da, +32.0564 Da and
+36.0757 Da, respectively. Peptides were queried using
full tryptic cleavage constraints with up to two missed
cleavage sites. The mass tolerances were 7 ppm for par-
ent masses and 0.5 Da for fragment masses. Phospho-
peptides with a Mascot score ≥ 30 (rank 1, P ≤ 0.05,
bold red required) were selected and quantified (FDR <
0.01). Phosphorylation site localisation and phosphopep-
tide quantification were performed using a dimethyl-
adapted version of MSQuant version 2.0a81. For each
peptide, the putative site of phosphorylation yielding the
highest posttranslational modification (PTM) score was
accepted (PTM score > 13 required, as described pre-
viously [15]). Peptide ratios were obtained by calculating
the extracted ion chromatograms of the light, medium
and heavy forms of the peptide using the monoisotopic
peaks only, and protein ratios were calculated from the
average of all quantified peptides. All MSQuant outputs
of the same online multidimensional separation were
then imported into StatQuant version 1.2.2, and the
quantified phosphopeptides were sorted together and
exported.
Substrate validation
1 μg recombinant HSP27 (Enzo Life Sciences, Farming-
d a l e ,N Y ,U S A ) ,r e c o m b i n a n tR p s 2 7( A b n o v a ,T a i p e i
City, Taiwan) or recombinant Smad9 (Abnova) were
diluted in 30 μl of 1× kinase assay buffer (20 mM
M O P S ,p H7 . 2 ,2 5m Mb-glycerophosphate, 5 mM
EGTA, 1 mM Na3VO4, 1 mM DTT, 25 mM MgCl2, 200
μMc o l dA T Pa n d2 . 5μCi [g-
32P]ATP). A quantity of
500 ng of p38a or p38b was then added, and the sam-
ples were assayed at 30°C for 1 hour. Laemmli buffer at
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assays, then the samples were electrophoresed and the
gels were dried and imaged. Peptide assays were per-
formed similarly with 5 μgo ft h ef o l l o w i n gp e p t i d e s
synthesised by Biomatik (Cambridge, ON, Canada):
HSP27 S180-APLPKAVTQSAEITIPVTF, HSP27 A180-
APLPKAVTQAAEITIPVTF, Rps27 S27-KHKKKRLVQ
SPNSYFMDVK, Rps27 A27-KHKKKRLVQAPNSYF
MDVK, Smad9 T136-NPYHYQRVETPVLPPVLVP and
Smad9 A136-NPYHYQRVEAPVLPPVLVP. The fre-
quency logo was generated using WebLogo [16].
Results
FSBA inhibits endogenous protein kinases
A substrate-finding approach that works with cell
lysate must overcome the obstacle of endogenous pro-
tein kinase activity. Lysate contains tens if not hun-
dreds of active kinases, making it difficult to attribute
individual phosphorylations that occur during a lysate-
based assay to a particular kinase. 5’-4-fluorosulphonyl-
benzoyladenosine (FSBA) offers a simple solution.
FSBA is an ATP analogue that inhibits protein kinases
by occupying the ATP binding site and covalently
attaching to an invariant lysine [17-20], the fully func-
tionally conserved and so-called catalytic lysine [21].
As FSBA irreversibly occupies the ATP binding site, a
bound kinase will permanently lose activity. Treatment
of whole-cell C2C12 myoblast lysate with this com-
pound can completely eliminate the endogenous kinase
signal present (Figure 1A).
Kinase-specific substrate labelling
Cell lysate treated with FSBA can be desalted to
remove any unbound inhibitor and a pool of protein
with no inherent kinase activity is generated. A kinase
of interest can then be added with a kinase assay buf-
fer, and any labelling that subsequently occurs is due
to the added kinase as opposed to an endogenous one.
To specifically label substrates of p38a,ak i n a s ea s s a y
buffer containing [g-
32P]ATP was added to FSBA-trea-
ted C2C12 lysate, along with recombinant p38a,a n d
the sample was assayed at 30°C. Substrates labelled by
p38a appeared as bands following one-dimensional gel
electrophoresis or as spots in two-dimensional gel elec-
trophoresis with no contaminating signal from endo-
genous kinases (Figure 1B and Additional file 1 Figure
S1). Although this type of approach is excellent for
visualising phosphorylation, it is very difficult to iden-
tify phosphorylated proteins through spot-picking and
MS. We therefore sought an alternative gel- and radio-
active-free approach for identifying phosphorylated
proteins.
Figure 1 FSBA is a pan-kinase inhibitor that allows for kinase-
specific substrate labelling of cell lysate. (A) C2C12 cell lysate
was treated with either nothing (lane 1), dimethyl sulphoxide
(DMSO) or 5’-4-fluorosulphonylbenzoyladenosine (FSBA) solubilised
in DMSO. Subsequently, samples were desalted, kinase assay buffer
containing
32P-g-ATP was added and the samples were assayed for
1.5 hours. Treatment with FSBA abolished the labelling of
endogenous protein kinase substrates. (B) After pretreatment of
C2C12 cell lysate with FSBA, purified p38a was added with a kinase
assay buffer to specifically label its substrates and visualised using
one-dimensional SDS-PAGE or two-dimensional gel electrophoresis
(Additional file 1 Figure S1).
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enrichment to identify substrates
The approach we devised to identify substrates is out-
lined in Figure 2. Cell lysate is treated with FSBA and
desalted as described in the previous section. This is fol-
lowed by the addition of a nonradioactive kinase assay
buffer, and the sample is split in two, to one of which is
added active kinase (kinase-added). After assaying at 30°
C, the two samples are digested, and peptides from each
sample are differentially tagged using isotopomeric
dimethyl labels. As a final step before MS, the samples
are combined and an enrichment for phosphopeptides is
performed using either TiO2 for serine/threonine phos-
phorylation or a phosphotyrosine antibody for tyrosine
phosphorylation. Phosphopeptides are then identified by
performing LC-MS/MS, and their relative abundance
between samples quantified by the differential dimethyl
labelling of peptides. Phosphopeptides that are more
abundant in the kinase-added sample are from proteins
labelled by the added kinase during the in vitro assay,
and by this means substrates can be identified. This
approach results not only in substrate identification but
also in the identification of the site of phosphorylation.
Because up to three samples can be compared using
dimethyl labelling, the phosphorylation profile of two
kinases (plus a control) can be compared in a single
experiment.
We began our initial in vitro substrate-finding proce-
dure by treating 1.5 mg of C2C12 lysate with FSBA. For
the assay, the sample was split into three equal parts,
with active p38a and b added to the second and third
samples, respectively. The rationale behind comparing
p38a with p38b was to identify specific p38a phosphor-
ylations that might explain why p38b cannot compen-
sate for the loss of p38a in differentiating myoblasts. In
total, 387 unique serine/threonine phosphopeptides
were identified (Additional file 1 Table S1). A histogram
of their relative abundance ratios (p38a/control) is
shown in Additional file 1 Figure S2. A threefold
increase in the abundance ratio was selected as a cutoff
for high-confidence in vitro substrates as this ratio is
beyond the range of inherent variability, and 158 phos-
phorylation sites from 94 different proteins showed at
least a threefold increase in the p38a-assayed sample
relative to the control. The list of p38a phosphorylation
sites is presented in Additional file 1 Table S2. We iden-
tified five previously known substrates (caldesmon, his-
tone H2B, Psmd1, SAKS1 and Smad3) and eighty-nine
that were previously unknown. Three of these previously
unknown targets were validated to determine if the
technique was discovering true in vitro p38a substrates.
Recombinant forms of these three proteins could be
phosphorylated in vitro by p38a (Figure 3A), and a vali-
dation of peptides confirmed the site of phosphorylation
(Figure 3B). After aligning substrates on their phosphor-
ylation sites, we found that a consensus phosphorylation
motif was present in many substrates, although it was
not an absolute requirement (Figure 3C). The motif
contains a proline immediately downstream from the
target serine or threonine and an aliphatic residue two
residues upstream. This motif is in agreement with that
previously described for p38 [22], providing further sup-
port for our substrate-finding approach.
Figure 2 Methodology used to identify in vitro kinase
substrates using FSBA and quantitative mass spectrometry. The
differential tagging of peptides with dimethyl labels allows for the
relative quantification and identification of phosphopeptides
simultaneously in a high-mass accuracy mass spectrometer. An
example/theoretical substrate identification for the added kinase
(green) is shown and is based on the higher intensity of the
phosphopeptide in MS.
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We first assayed p38a and p38b on cell lysate using the
radioactive approach and were surprised to see no
obvious differences in the substrate banding patterns
produced by the two isoforms (Figure 4A). Consistent
with this observation, of the 158 p38a phosphorylations
identified using the quantitative approach, none
appeared to be specific to this isoform. The 158 quanti-
tative values for the p38a phosphorylations are plotted
from highest to lowest in Figure 4B (blue line for p38a).
The red line represents the corresponding p38b values.
Although p38a and p38b showed apparent differences
in preference, they had very similar overall profiles.
There were only four phosphorylations that fell above
the threefold cutoff for p38a,w h e r e a sf o rp 3 8 b they
were well below. However, the values were still positive
for p38b, suggesting that these could be real phosphory-
lations but there is simply less confidence in them. To
determine if these might represent specific phosphoryla-
tions, we performed in vitro assays with either p38a or
p38b using purified substrate for one candidate. The
purified substrate was the 40S ribosomal protein S27
(Rps27), and both p38 isoforms were able to phosphory-
late this protein at the same site (Figure 4C and 4D).
Figure 3 Validation of newly discovered p38a substrates. (A)
Validation of three newly identified targets as in vitro p38a
substrates was performed using full-length substrate incubated with
a kinase assay buffer and p38a. (B) Wild-type peptides containing
the phosphorylation site or peptides harbouring an S/T-to-A
mutation of the phosphorylation site were incubated with p38a
and a kinase assay buffer to confirm the location of the
phosphorylation site. (C) The 158 phosphorylation sites identified
were aligned, and a frequency logo was generated. p38a has a
consensus phosphorylation motif of aXS/TP, where “a” is an aliphatic
residue and “X” is any amino acid.
Figure 4 Localisation, not substrate specificity, distinguishes
p38a from p38b. (A) FSBA-treated C2C12 cell lysate was incubated
with a kinase assay buffer and p38a, p38b or no kinase as a control.
Both isoforms produced similar banding patterns. The prominent
bands marked with the asterisks in each of the p38a and p38b
lanes represent autophosphorylation of the added recombinant
kinase. (B) The quantitative values for all 158 identified p38a
phosphorylations are plotted in blue on a log2 scale, with the
corresponding values for p38b shown in red. The dashed line
represents the fold cutoff for accepted substrates. Four p38b
phosphorylations fell appreciably below the fold cutoff (point 2
corresponds to serine 27 of the 40S ribosomal protein S27-Rps27).
(C) Incubation of p38a or p38b with purified Rps27 and a kinase
assay buffer. (D) Incubation of p38a or p38b with a peptide from
Rps27 containing serine 27 (or mutation of serine 27 to alanine) and
a kinase assay buffer. (C) and (D) demonstrate that serine 27 of
Rps27 is not a specific p38a phosphorylation site. (E) FLAG-tagged
p38a or p38b were transfected into C2C12 cells, and at 48 hours of
differentiation immunofluorescence staining for FLAG was
performed. p38a has a ubiquitous distribution, whereas p38b is
found solely at the cell periphery. Cells were imaged using a Zeiss
LSM 510 META confocal microscope (Carl Zeiss MicroImaging
GmbH, Jena, Germany). Scale bar = 20 μm.
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p38a appear to be specific to this isoform.
If substrate specificity does not distinguish the two
p38 isoforms, and yet p38b is unable to compensate for
the loss of p38a, there must be an alternative character-
istic that discriminates them. An obvious possibility is
cellular localisation. If p38a and p38b localise differently
within the cell, then p38b w o u l ds i m p l yb eu n a b l et o
fulfil p38a’s role, even though it might have the catalytic
potential to do so. To study this, we overexpressed
FLAG-tagged p38a and p38b in C2C12 cells and
assessed their localisation during differentiation (Figure
4E). Whereas p38a has a ubiquitous localisation pattern,
p38b is found only at the periphery of the cell. p38a
therefore has access to a substrate pool that p38b does
not, highlighting a major reason why p38b cannot com-
pensate for the loss of p38a.
Identification of novel in vivo p38a substrates
Although the approach we have outlined can identify in
vitro kinase substrates, such in vitro approaches will also
turn up irrelevant substrates that are phosphorylated
only because of the absence of the appropriate cellular
context. For example, we identified just over 400 phos-
phorylation sites in the screen described above, 158 of
which are in vitro p38 targets. If these numbers are
representative, it suggests that p38 could be responsible
for approximately 40% of all cellular phosphorylations in
differentiating myoblasts, a number that seems unlikely,
given that there are about 500 mouse and human
kinases [23].
To overcome the drawbacks associated with in vitro
substrate identification, we modified the approach to
allow for the identification of relevant, direct in vivo
substrates (outlined in Figure 5). For our purposes, dif-
ferentiating C2C12 cells were treated either with the
p38 inhibitor SB 202190 or with DMSO as vehicle prior
to lysis. SB inhibitor or vehicle treatment began at 48
hours of differentiation, and the cells were lysed 24
hours later. The 48-hour time point was chosen because
of our interest in identifying novel functions for p38a
during the middle stages of myoblast differentiation.
Myogenic gene activation occurs within the first 48
hours of differentiation [24] and is followed by cell
fusion, sarcomere formation and other processes. If dif-
ferentiating C2C12 myoblasts are treated with a p38
inhibitor at 48 hours, there is a reduction in cell fusion
and overall differentiation (Additional file 1 Figure S3),
indicating that there is a requirement for long-term p38
activity for efficient myogenesis beyond the initial stage
of myogenic gene activation, possibly both for maintain-
ing such gene activation and for fusion-related pro-
cesses. Following cell lysis, a 1-mg aliquot was taken
from the lysate of vehicle-treated cells and two 1-mg
aliquots were taken from the lysate of inhibitor-treated
cells. All three aliquots were treated with FSBA and
desalted to remove unbound FSBA and SB inhibitor,
and a kinase assay buffer was added to each. Active
p38a was added to one of the inhibitor-treated aliquots,
and the samples were assayed at 30°C. Following the
assay, the samples were digested, dimethyl-labelled and
phosphopeptides enriched as described above. What we
sought to identify were phosphorylation sites that
decreased on inhibitor treatment and could be elevated
back up by direct in vitro p38a labelling of SB inhibitor-
treated lysate. These would be direct phosphorylation
sites regulated by p38a in vivo.
By using this approach, we identified a total of 717
phosphorylation sites (Additional file 1 Table S3), 73 of
Figure 5 Methodology used to identify in vivo kinase
substrates using FSBA and quantitative MS. In vivo substrates are
identified based on the higher phosphopeptide intensity in MS for
both the vehicle-treated (blue) and kinase-added (green) samples. A
higher phosphopeptide abundance in MS for the vehicle-treated
(blue) sample relative to the inhibitor-treated (red) sample indicates
a phosphorylation site regulated by the kinase of interest in vivo.A
higher phosphopeptide abundance for the kinase-added (green)
sample relative to the inhibitor-treated (red) sample indicates a
phosphorylation site directly targeted by the kinase in vitro.
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tor treatment, and seven of these sites were direct p38a
phosphorylation sites (that is, showed at least a threefold
increase in the p38a-labelled sample relative to the
lysate from inhibitor-treated cells). In contrast to the
pure in vitro approach, which suggested that approxi-
mately 40% of all cellular phosphorylations might be
p38 target sites, the numbers derived from the in vivo
study suggest that the actual level is closer to about 1%.
The seven in vivo sites (on six substrates) that we iden-
tified are listed in Table 1.
The substrate Iws1 is a largely nuclear protein
involved in several processes, such as chromatin remo-
delling and mRNA export [25,26], functions with which
p38 has previously been associated. Ranbp2 localises
predominantly to the nuclear pore complex and is criti-
cal for myotube formation [27]. The other four sub-
strates are cytoplasmic proteins without known or
suggested nuclear functions (Ahnak, Grp78, Pgrmc and
Prdx6). On the basis of fractionations and Western blot
analysis, we found that p38a was indeed present in the
cytoplasm during differentiation (Figure 6A), which is in
agreement with the immunofluorescence staining of
FLAG-tagged p38a. The levels of phosphorylated p38,
the active form, increased in the cytoplasm with differ-
entiation (Figure 6A and Additional file 1 Figure S4),
suggesting that p38a might play an important role
there. Validation of the phospho-p38 antibody is shown
in Additional file 1 Figure S5. Further fractionation of
the cytoplasm revealed that p38a and phospho-p38
were present only in the cytosolic fraction (Figure 6B),
meaning that all four of the in vivo cytoplasmic phos-
phorylation sites we identified would be accessible to
p38a. Using Scansite [28], we found that five of the six
substrates contained one or more predicted D domains,
MAPK docking domains found on many in vivo sub-
strates (D domain sites and scores are listed in Addi-
tional file 1 Table S4). We next used Genemania [29] to
identify previously known associations between these
substrates and the p38 activation pathway we recently
reviewed and outlined [30]. Four of the substrates have
previously known associations with this pathway (Figure
6C), providing additional support that these targets are
relevant and that their phosphorylation could be critical
for pathway function.
Discussion
We have described here a simple technique for kinase
substrate finding that uses whole-cell lysate, can identify
sites of phosphorylation in addition to the protein phos-
phorylated, has the ability to identify both in vivo and in
vitro substrates, and can be used to compare the in vitro
substrate specificity of two kinases in the same
Table 1 Newly discovered in vivo p38a substrates
Genes Protein names Sites
Ahnak Neuroblast differentiation-associated protein AHNAK S4906
Iws1 Protein IWS1 homolog S183,
S185
Grp78 78 kDa glucose-regulated protein T649
Pgrmc Membrane-associated progesterone receptor
component 1
S181
Prdx6 Peroxiredoxin 6 T93
Ranbp2 E3 SUMO
a protein ligase RanBP2 S2505
aSUMO, small ubiquitin-like modifier.
Figure 6 Cytoplasmic characterization of p38a during C2C12
cell differentiation. (A) C2C12 cells were fractionated over a
differentiation time course. C, control whole-cell lysate; P,
proliferating lysate. Western blotting for phospho-p38 shows a clear
increase in the cytoplasm as differentiation proceeds. Nuclei were
removed in the initial step of fractionation, and lamin A/C was used
to demonstrate that there were no contaminating nuclei in
cytoplasmic extracts. Quantification of phospho-p38 expression is
shown in Additional file 1 Figure S4. (B) After 48 hours of
differentiation, C2C12 cells were lysed and the cytoplasmic fraction
was collected and further fractionated into cytosolic (including the
cytoskeleton) and noncytosolic fractions. Nuclear marker: lamin A/C;
cytoskeletal marker: a-actinin; mitochondrial marker: COX IV;
membrane marker: neural cell adhesion molecule (NCAM);
endoplasmic reticulum marker: GRP78. (C) Interconnections
between the p38a activation pathway and newly discovered in vivo
substrates. Proteins previously associated with p38a in its activation
pathway are indicated as blue nodes. New substrates are indicated
as red nodes. Edge colouring indicates the type of association
between nodes.
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revealed that, although differences in preference are
apparent, there are no obvious phosphorylation sites
specific to p38a. However, a major characteristic that
distinguishes p38a from p38b during myoblast differen-
tiation is localisation, with p38a located ubiquitously
throughout the cell while p38b is found only at the cell
periphery. We also have shown that p38a can phos-
phorylate several cytosolic phosphorylation sites in vivo
and that this may be a critical but previously unknown
function for it. These results demonstrate the utility of
the substrate screening technique we have developed
and how its use not only can find proteins phosphory-
lated by a kinase of interest but also can answer particu-
lar questions and propose novel avenues of research.
The technique we have developed has several advan-
tages over existing substrate finding approaches. It can
provide direct substrate identifications and information
on in vivo relevance in a single experiment. Whole-cell
lysate can be used as a source of candidate substrates,
allowing screens to be performed on samples of specific
relevance to the area of interest instead of on protein or
peptide arrays. Our approach for eliminating endogen-
ous kinase activity in lysate is nondenaturing, decreasing
the likelihood of false-positive and false-negative sub-
strate phosphorylations that would result from the heat-
inactivating approach that others have employed [31,32].
At the same time, the recombinant kinase used in the
assay does not require mutation or unnatural ATP ana-
logues as other approaches do [33], making the techni-
que applicable to any kinase that can be made and
purified in an active form. Although we used dimethyl
labelling for quantitative MS, the technique is fully com-
patible with iTRAQ, which allows up to eight samples to
be compared in a single experiment, meaning that
simultaneous in vivo substrate identification and kinase
comparisons can be performed. Radioactivity and gel
work are not required, but can be used to visualise
phosphorylations and make qualitative comparisons
between kinases on one-dimensional gels. The lysate
requirements are also relatively low; 1.5 to 3 mg were
used in these assays, which may make the technique dif-
ficult to employ with some primary cells lines, but it is
easily applicable to most secondary cell lines and to tis-
sues as well. We have treated several different lysate
types with FSBA, and complete inhibition of endogen-
ous kinase activity occurred in all, meaning that our
approach is likely universally applicable. In this study
our approach for identifying in vivo substrates utilised
an inhibitor, but it is more versatile than that, and can
be applied to study phosphorylations triggered by a spe-
cific stimulus (using stimulated versus unstimulated
cells for lysate pools) without requiring a specific inhibi-
tor be available. Finally, although we have performed
the in vivo approach on unfractionated lysate, when
combined with fractionation prior to LC-MS/MS, the
number of substrates identified could be much greater
than what we have demonstrated in principle here.
As mentioned, a major advantage of the technique
presented here is that it can be used to compare the
substrate profiles of two or more kinases, and we used
this to study the substrate specificity of the p38a and b
isoforms. However, we were unable to identify any phos-
phorylations that were specific to p38a.T h e r ea r e
apparent differences in preference for substrates
between p38a and p38b, which could be functionally
relevant. Assuming that p38b had the same ubiquitous
localisation pattern as p38a, a low preference for certain
critical myogenic phosphorylations could result in a dif-
ference in cell behaviour if p38b w e r et h eo n l yi s o f o r m
present. However, it seems likely that differentiation
would still occur, but possibly at a reduced rate or in a
compromised way. This is not the case, as p38b-con-
taining myoblasts that lack p38a fail to differentiate at
all [7-9,34]. Rather, we believe what truly distinguishes
the two isoforms is their localisation. p38a has a known
critical role in the nucleus, and our results suggest that
the same may be true for the cytoplasm; therefore, p38b
would be unable to compensate because it is found
solely at the periphery of the cell. A similar distinction
exists for two other closely related kinases, focal adhe-
sion kinase (FAK) and proline-rich tyrosine kinase 2
(PYK2) [35]. In fibroblasts, FAK localises to focal adhe-
sions, whereas PYK2 has a perinuclear distribution.
PYK2, which has a kinase domain 60% identical to that
of FAK, can compensate for the loss of FAK provided it
has a focal adhesion targeting sequence. Together these
results suggest that rather than substrate specificity, it is
other characteristics, in these cases localisation, that dis-
tinguish closely related kinases. Whether the same holds
true for the entire kinase family is an intriguing
question.
In addition to p38a’s known role in regulating gene
expression at the onset of myoblast differentiation, our
results suggest that it is likely to have a cytosolic role as
well, possibly in regulating its own pathway. We have
found that p38a is present in the cytosol, active p38
increases in the cytoplasm with differentiation, p38a can
phosphorylate several cytosolic proteins, three of the
cytosolic proteins contain predicted D domains, and
connections between these proteins and the p38a acti-
vation pathway have been previously reported. Together
these results suggest a previously unrecognised role for
p38a in the cytosol.
Conclusions
While the role of the p38a MAPK during myoblast dif-
ferentiation has been studied extensively with regard to
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Page 10 of 12gene regulation, our evidence suggests that this kinase is
likely involved in other processes as well. The differen-
tiation of myoblasts into a mature myotube involves
extensive morphological and functional changes that
p38a might regulate, both through the initiation of a
myogenic gene program and through direct phosphory-
lation and functional modification of cytosolic proteins.
No one has previously been able to identify a p38a-spe-
cific substrate, and our large-scale screen suggests these
may exist only within the context of cellular localisation.
In addition, the substrate screening technique we have
developed should serve as a useful tool for studying the
other kinases known to be involved in myogenesis, as
well as the hundreds of other protein kinases that exist.
Additional material
Additional file 1: Figures S1 through S5 and Tables S1 through S4.
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